Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TERT | O14746 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 5/20 | 0.47 |
| ▸ | BCHE | P06276 | 4/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9594726 | 0.89 | KDM4E (0.57) | APPMEN1KMT2ALMNAKDM4E | |
| SCHEMBL12285138 | 0.86 | KDM4E (0.55) | APPMEN1KMT2ALMNAKDM4E | |
| SCHEMBL25757947 | 0.85 | APP (0.74) | APPMEN1KMT2ATERTABCB11 | |
| SCHEMBL31038657 | 0.85 | KDM4E (0.68) | APPMEN1KMT2ALMNATHRB | |
| SCHEMBL2448633 | 0.85 | KDM4E (0.68) | APPMEN1KMT2ALMNATHRB | |
| SCHEMBL30603139 | 0.85 | KDM4E (0.68) | APPMEN1KMT2ALMNATHRB | |
| SCHEMBL26356180 | 0.84 | KDM4E (0.52) | APPMEN1KMT2ALMNAKDM4E | |
| SCHEMBL14126140 | 0.83 | KDM4E (0.62) | APPMEN1KMT2ALMNAKDM4E | |
| SCHEMBL31500228 | 0.83 | KDM4E (0.61) | APPMEN1KMT2ALMNAKDM4E | |
| SCHEMBL13739299 | 0.81 | KMT2A (0.61) | MEN1KMT2ALMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329258-B2 | CGAS in systemic lupus erythematosus (SLE) | UNIVERSITY OF WASHINGTON (US) | 2019-06-25 | — | — | US | disclosed |
| US-10329258-B2 | CGAS in systemic lupus erythematosus (SLE) | UNIVERSITY OF WASHINGTON (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180086713-A1 | CGAS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | UNIVERSITY OF WASHINGTON | 2018-03-29 | — | — | US | disclosed |
| US-20180086713-A1 | CGAS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | UNIVERSITY OF WASHINGTON | 2018-03-29 | — | — | US | disclosed |
| US-20180086713-A1 | CGAS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | UNIVERSITY OF WASHINGTON | 2018-03-29 | — | — | US | disclosed |
| WO-2016176222-A1 | CGAS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | UNIVERSITY OF WASHINGTON (US) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016176222-A1 | CGAS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | UNIVERSITY OF WASHINGTON (US) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086713-A1 | CGAS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | STING1, IRF3, CGAS | APP 3191/4885MEN1 1533/4885KMT2A 3147/4885 |
| US-10329258-B2 | CGAS in systemic lupus erythematosus (SLE) | STING1, IRF3, CGAS | APP 3191/4885MEN1 1533/4885KMT2A 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.